原发性胆道胆道炎的新兴治疗方法
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
概括
原发性胆道胆道炎 (PBC) 的新疗法显示出有前途. 选择性PPAR激动剂和其他新兴疗法为患有这种自身免疫性肝病的患者提供了改进的选择,解决了超出ursodeoxycholic acid之外的未满足需求.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 初级胆道胆炎 (PBC) 是一种自身免疫性肝脏疾病,导致胆道逐渐破坏.
- 乌尔苏多氧胆酸 (UDCA) 是标准的第一线疗法,但许多患者的反应不足.
- 现有的二线治疗方法,如奥贝蒂科尔酸,具有局限性,包括不良影响.
研究的目的:
- 审查初级胆道胆道炎治疗的近期进展.
- 突出新型治疗剂及其潜在益处.
- 讨论改善患者管理的新兴选择.
主要方法:
- 对新型PBC疗法的最新临床试验数据的审查.
- 对药理学标和作用机制的分析.
- 评估新治疗方式的安全性和有效性概况.
主要成果:
- 选择性多氧酶增殖器激活受体 (PPAR) 激动剂 (seladelpar,elafibranor) 在III期试验中显示出显著的疗效和良好的安全性.
- 新兴的针对症状的疗法,如NOX抑制剂和叶胆酸载体抑制剂,提供了额外的管理策略.
- 这些进展扩大了PBC患者的治疗选择.
结论:
- 新型药物,特别是PPAR激动剂,代表了PBC治疗的重大进展.
- 新兴的治疗方法为有效管理PBC及其症状提供了新的希望.
- 这些进展有望改善原发性胆道胆炎患者的治疗结果.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
Chronic Pancreatitis II: Collaborative Care
128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
128
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
Chronic Bowel Disorders: Introduction
541
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
541
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239

